Cargando…
Novel lipophilic SN38 prodrug forming stable liposomes for colorectal carcinoma therapy
Background: SN38 (7-ethyl-10-hydroxy camptothecin), as a potent metabolite of irinotecan, is highly efficacious in cancer treatment. However, the clinical utility of SN38 has been greatly limited due to its undesirable properties, such as poor solubility and low stability. Materials and methods: In...
Autores principales: | Xing, Jing, Zhang, Xiquan, Wang, Zhe, Zhang, Huanqing, Chen, Peng, Zhou, Gaoxin, Sun, Chunlong, Gu, Ning, Ji, Min |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6634269/ https://www.ncbi.nlm.nih.gov/pubmed/31371956 http://dx.doi.org/10.2147/IJN.S204965 |
Ejemplares similares
-
Novel SN38 derivative-based liposome as anticancer prodrug: an in vitro and in vivo study
por: Wu, Chan, et al.
Publicado: (2018) -
PEGylation of lipophilic SN38 prodrug with DSPE-mPEG(2000) versus cremophor EL: comparative study for intravenous chemotherapy
por: Zeng, Jun, et al.
Publicado: (2019) -
Liposomal codelivery of an SN38 prodrug and a survivin siRNA for tumor therapy
por: Bi, Ye, et al.
Publicado: (2018) -
Lipophilic Prodrug of Methotrexate in the Membrane of Liposomes Promotes Their Uptake by Human Blood Phagocytes
por: Tretiakova, D. S., et al.
Publicado: (2020) -
Phosphatidylinositol Stabilizes Fluid-Phase Liposomes Loaded with a Melphalan Lipophilic Prodrug
por: Tretiakova, Daria, et al.
Publicado: (2021)